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Diabetes may affect cardiac structure and function independent
to atherosclerosis and hypertension. Considering the increased risk of
heart failure and cardiovascular event in diabetic cardiomyopathy,
investigation of etiology and mechanism of this unique entity is im-
portant for developing potential therapy. Endothelin-1 (ET-1) has been
associatedwith development of diabetic cardiomyopathy in pre-clinical
study. This study aims to investigate correlation of plasma ET-1 with
development of myocardial ﬁbrosis and diastolic dysfunction in dia-
betes patient. Forty-one diabetes and non-diabetes patient with no
history of myocardial infarction were recruited. Plasma ET-1 level was
measured with radioimmunoassay, diastolic function was evaluated by
Doppler echocardiography, and diffuse myocardial ﬁbrosis was evalu-
ated by post-contrast myocardial T1-relaxation time using cardiac MRI.
Plasma ET-1 level is higher in diabetes group as compared to non-
diabetes (1.48 ± 0.50 vs. 1.08 ± 0.22 pg/ml, p b 0.05). All diabetes
subjects developed diastolic dysfunction, with 17 (85%) having grade
2 and 3 diastolic dysfunction, compared to 13 (61.9%) non-diabetes
patient who showed normal diastolic function. Patient with grade 3
(severe) diastolic dysfunction showed higher plasma ET-1 level as
compared to patient with normal diastolic function (1.78 ± 0.50 vs.
1.09 ± 0.19 pg/ml, p b 0.05). Diabetes subject had shorter post-contrast
T1-relaxation time-reﬂecting diffuse myocardial ﬁbrosis (440.97 ±
16.97 vs. 489.41 ± 6.73 ms, p b .005), and correlates inversely to
plasma ET-1 level (Spearman Coeff R =−0.394, p b 0.05). In conclusion,
higher plasma endothelin-1 level is associated with diffuse myocardial
ﬁbrosis and diastolic dysfunction in diabetes patient. This may provide
additional evidence for the potential clinical use of endothelin-receptor
blockade in preventing diabetic cardiomyopathy.
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Childhood obesity is an independent risk factor for cardiovascular
diseases; however, the mechanisms of vascular alterations early in
obesity remain unknown. Endothelin-1 plays a major role on vas-
cular dysfunction in adiposity-related cardiovascular pathologies.
Endothelin-1 induces vasoconstriction by RhoA/Rho-kinase and/or
PKC pathway activation. Endothelin-1 also activates vascular ERK1/2.
We hypothesized that early in obesity, endothelin-1-mediated acti-
vation of PKC/ERK1/2 augments vascular contraction in obese Zucker
rats (OZRs). Aortic rings from young (6–7 week-old) OZRs and their
lean counterparts were used. The isometric contraction to phenyl-
ephrine, U46619 (TXA2 mimetic), endothelin-1 and phorbol 12,13-
dibutyrate (PKC activator) was increased in aorta from OZRs. The
increased phenylephrine- and endothelin-1-induced vasoconstric-
tion was corrected by inhibitors of PKC (GF-109203X) or MEK1/2
(U0126 and PD98059). The Rho-kinase inhibitor (Y-27632) did not
change the contractile responses in OZRs. Vasorelaxation to Y-27632
was also similar in both groups. The ETA antagonist (BQ123) de-
creased endothelin-1-induced response and corrected the increased
phenylephrine-induced contraction in OZRs. Western immunoblot
indicated decreased ETA receptor expression in OZRs. Phosphoryla-
tion of PKC-alpha was decreased while PKC-beta did not change
in OZRs. In contrast, OZRs displayed increased phosphorylation of
MEK1/2, ERK1/2, PKC-epsilon and CPI-17, accompanied by decreased
phosphorylation of the MAPK phosphatase (MKP-1). The increased
phosphorylation of ERK1/2 in OZRswas corrected by either GF109203X
or BQ123. Total calponin was decreased while MARCKs phosphory-
lation was not changed in OZRs. These results indicate that activation
of endothelin-1-mediated PKC-epsilon/ ERK1/2 pathway contributes
to augment the contractile responses in aorta from young OZRs,
providing evidence for a role of the endothelin-1 system on the
impairment of the vascular function early in obesity. Funding: CNPq
and FAPESP.
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